Genetic vaccination against leishmaniasis.
The gene encoding for a major surface glycoprotein, gp63, of Leishmania major was cloned into the eukaryotic expression plasmid pCDNAI with CMV or RSV promoters. The highly susceptible Balb/c mice were injected intramuscularly with 100 micrograms/mouse of the purified plasmid. The plasmids were found to be stable in vivo for at least 40 days after injection and expressed significant levels of gp63, demonstrable by immunohistological staining with specific antibody. The immunized mice developed significant resistance against L. major infection compared to controls similarly immunized with the empty plasmid. Spleen cells from the immunized mice produced significant levels of IL-2 and IFN-gamma but no detectable IL-4 when cultured with leishmanial antigens in vitro.
Xu
D
D
Department of Immunology, University of Glasgow, Western Infirmary, UK.
Liew
F Y
FY
D000818:Animals; D005822:Genetic Vectors; D007371:Interferon-gamma / Q000276:immunology; D007896:Leishmaniasis / Q000276:immunology* / Q000517:prevention & control*; D008666:Metalloendopeptidases / Q000235:genetics / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D016052:Protozoan Vaccines / Q000276:immunology*
D016052:Protozoan Vaccines; D007371:Interferon-gamma; D008666:Metalloendopeptidases; C055146:glycoprotein gp63, Leishmania